Cargando…

Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis

BACKGROUND: Despite improvement in the overall survival of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, the effects of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment on bone metastasis remain unclear. This study investigated radiol...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyagi, Michihito, Katagiri, Hirohisa, Murata, Hideki, Wasa, Junji, Takahashi, Toshiaki, Murakami, Haruyasu, Harada, Hideyuki, Mori, Keita, Takahashi, Mitsuru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801654/
https://www.ncbi.nlm.nih.gov/pubmed/36581856
http://dx.doi.org/10.1186/s12890-022-02226-1
_version_ 1784861536621166592
author Miyagi, Michihito
Katagiri, Hirohisa
Murata, Hideki
Wasa, Junji
Takahashi, Toshiaki
Murakami, Haruyasu
Harada, Hideyuki
Mori, Keita
Takahashi, Mitsuru
author_facet Miyagi, Michihito
Katagiri, Hirohisa
Murata, Hideki
Wasa, Junji
Takahashi, Toshiaki
Murakami, Haruyasu
Harada, Hideyuki
Mori, Keita
Takahashi, Mitsuru
author_sort Miyagi, Michihito
collection PubMed
description BACKGROUND: Despite improvement in the overall survival of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, the effects of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment on bone metastasis remain unclear. This study investigated radiological responses to gefitinib regarding bone metastasis in patients. METHODS: We treated 260 patients with NSCLC and symptomatic bone metastasis. Thirty-seven patients harboring EGFR mutation were treated with gefitinib for more than 30 days and followed up for more than 3 months (GEF group). We performed a retrospective observational study by selecting 36 cases without EGFR-TKI treatment, at least 3 months of follow-up, and at least two radiological evaluations as the control group. We assessed the best overall radiological response, interval from treatment initiation to appearance of a radiological response, and the local response maintenance rate. RESULTS: The best effect in the GEF group was 98% partial response or better, which was significantly higher than the 57% observed in the control group (p < 0.001). The GEF and control groups maintained 83% and 42% local response maintenance rates at one year, respectively (p < 0.001). In the GEF with radiotherapy group, the local response maintenance rate was maintained at 92% at 1 year, while in the GEF without RT group, there was a decrease in the local response maintenance rate from 270 days. CONCLUSION: Gefitinib treatment for bone metastases in patients harboring EGFR mutation resulted in a beneficial osteosclerotic change in most patients. Combined gefitinib and radiotherapy provide long-lasting local control of bone metastases.
format Online
Article
Text
id pubmed-9801654
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98016542022-12-31 Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis Miyagi, Michihito Katagiri, Hirohisa Murata, Hideki Wasa, Junji Takahashi, Toshiaki Murakami, Haruyasu Harada, Hideyuki Mori, Keita Takahashi, Mitsuru BMC Pulm Med Research Article BACKGROUND: Despite improvement in the overall survival of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, the effects of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment on bone metastasis remain unclear. This study investigated radiological responses to gefitinib regarding bone metastasis in patients. METHODS: We treated 260 patients with NSCLC and symptomatic bone metastasis. Thirty-seven patients harboring EGFR mutation were treated with gefitinib for more than 30 days and followed up for more than 3 months (GEF group). We performed a retrospective observational study by selecting 36 cases without EGFR-TKI treatment, at least 3 months of follow-up, and at least two radiological evaluations as the control group. We assessed the best overall radiological response, interval from treatment initiation to appearance of a radiological response, and the local response maintenance rate. RESULTS: The best effect in the GEF group was 98% partial response or better, which was significantly higher than the 57% observed in the control group (p < 0.001). The GEF and control groups maintained 83% and 42% local response maintenance rates at one year, respectively (p < 0.001). In the GEF with radiotherapy group, the local response maintenance rate was maintained at 92% at 1 year, while in the GEF without RT group, there was a decrease in the local response maintenance rate from 270 days. CONCLUSION: Gefitinib treatment for bone metastases in patients harboring EGFR mutation resulted in a beneficial osteosclerotic change in most patients. Combined gefitinib and radiotherapy provide long-lasting local control of bone metastases. BioMed Central 2022-12-29 /pmc/articles/PMC9801654/ /pubmed/36581856 http://dx.doi.org/10.1186/s12890-022-02226-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Miyagi, Michihito
Katagiri, Hirohisa
Murata, Hideki
Wasa, Junji
Takahashi, Toshiaki
Murakami, Haruyasu
Harada, Hideyuki
Mori, Keita
Takahashi, Mitsuru
Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
title Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
title_full Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
title_fullStr Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
title_full_unstemmed Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
title_short Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
title_sort osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801654/
https://www.ncbi.nlm.nih.gov/pubmed/36581856
http://dx.doi.org/10.1186/s12890-022-02226-1
work_keys_str_mv AT miyagimichihito osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis
AT katagirihirohisa osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis
AT muratahideki osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis
AT wasajunji osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis
AT takahashitoshiaki osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis
AT murakamiharuyasu osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis
AT haradahideyuki osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis
AT morikeita osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis
AT takahashimitsuru osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis